Table 3.
Cause-specific hazard and proportional subdistribution hazard among Hodgkin lymphoma patients for categorized SMN subtypes, taking SEER rules for the SMN definition.
| Non-Hispanic Black vs. Non-Hispanic white | Hispanic vs. Non-Hispanic white | Asian/other vs. Non-Hispanic white | ||||
|---|---|---|---|---|---|---|
| CSH (95% CI) | PSH (95% CI) | CSH (95% CI) | PSH (95% CI) | CSH (95% CI) | PSH (95% CI) | |
| Skin excluding basal and squamous | NA | NA | 0.24 (0.09 to 0.65)* | 0.22 (0.08 to 0.59)* | 0.26 (0.06 to 1.04) | 0.23 (0.06 to 0.93)* |
| Oral cavity and pharynx | 0.43 (0.13 to 1.39) | 0.40 (0.12 to 1.29) | 0.49 (0.18 to 1.35) | 0.43 (0.15 to 1.20) | 1.21 (0.44 to 3.36) | 1.07 (0.38 to 2.98) |
| Digestive system | 1.45 (0.97 to 2.17) | 1.38 (0.92 to 2.08) | 1.51 (1.04 to 2.21)* | 1.34 (0.91 to 1.96) | 1.10 (0.58 to 2.09) | 0.97 (0.51 to 1.86) |
| Female breast | 1.56 (1.03 to 2.36)* | 1.43 (0.95 to 2.17) | 0.62 (0.35 to 1.10) | 0.55 (0.31 to 0.98)* | 0.62 (0.27 to 1.40) | 0.55 (0.25 to 1.24) |
| Respiratory system | 1.09 (0.71 to 1.69) | 1.04 (0.67 to 1.62) | 0.52 (0.29 to 0.91)* | 0.45 (0.26 to 0.79)* | 0.30 (0.09 to 0.93)* | 0.26 (0.08 to 0.82)* |
| Genital system | 1.33 (0.89 to 1.99) | 1.26 (0.85 to 1.88) | 0.73 (0.45 to 1.19) | 0.65 (0.40 to 1.07) | 0.97 (0.51 to 1.85) | 0.87 (0.46 to 1.64) |
| Urinary system | 0.83 (0.41 to 1.66) | 0.80 (0.39 to 1.62) | 0.74 (0.37 to 1.49) | 0.68 (0.34 to 1.38) | 0.20 (0.03 to 1.43) | 0.18 (0.03 to 1.30) |
| Endocrine system | 0.35 (0.13 to 0.95)* | 0.33 (0.12 to 0.91)* | 1.31 (0.78 to 2.17) | 1.24 (0.75 to 2.07) | 0.50 (0.16 to 1.59) | 0.47 (0.15 to 1.53) |
| Other solid tumor | 0.79 (0.34 to 1.86) | 0.74 (0.32 to 1.71) | 0.78 (0.35 to 1.73) | 0.72 (0.33 to 1.61) | 1.86 (0.84 to 4.10) | 1.75 (0.81 to 3.78) |
| NHL | 0.81 (0.55 to 1.19) | 0.78 (0.54 to 1.14) | 0.84 (0.58 to 1.22) | 0.77 (0.53 to 1.12) | 1.59 (1.05 to 2.41)* | 1.48 (0.98 to 2.25) |
| Leukemia | 0.93 (0.52 to 1.66) | 0.89 (0.50 to 1.59) | 1.21 (0.75 to 1.94) | 1.10 (0.67 to 1.78) | 0.98 (0.45 to 2.11) | 0.90 (0.42 to 1.92) |
| Other hematologic malignancy | 0.75 (0.29 to 1.90) | 0.72 (0.28 to 1.83) | 0.70 (0.28 to 1.76) | 0.62 (0.25 to 1.55) | 1.30 (0.47 to 3.62) | 1.15 (0.42 to 3.19) |
*p < 0.05.
An SMN diagnosis was assigned to patients who developed a malignancy at least 2 months after the index Hodgkin lymphoma diagnosis according to the criteria for multiple primary cancers developed by SEER program. All these hazards were adjusted by age, gender, diagnosis year of Hodgkin lymphoma, Ann Arbor stage, histology, Yost index, and treatment as appropriate.
SMN, second malignant neoplasm; NHL, non-Hodgkin lymphoma; SEER, Surveillance, Epidemiology, and End Results. NA, not available.